Arthritis/rheumatic disorders:
Indications for COSENTYX:
Active psoriatic arthritis (PsA). Ankylosing spondylitis (AS). Active non-radiographic axial spondyloarthritis (nraxSpA) in adults with objective signs of inflammation.
Adult Dosage:
Rotate inj site (eg, upper arms, thighs, or any quadrant of abdomen). ≥18yrs: PsA with coexistent plaque psoriasis: 300mg (given as two 150mg SC injections) at Weeks 0, 1, 2, 3, and 4 then 300mg every 4 weeks. Other PsA (with a loading dose): 150mg by SC inj at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter; (without a loading dose): 150mg every 4 weeks. Consider 300mg every 4 weeks if PsA continues. Cosentyx may be administered with or without MTX. AS (with a loading dose): 150mg by SC inj at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter; (without a loading dose): 150mg every 4 weeks. Consider 300mg every 4 weeks if AS continues. nraxSpA (with a loading dose): 150mg by SC inj at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter; (without a loading dose): 150mg every 4 weeks.
Children Dosage:
<18yrs: not evaluated.
COSENTYX Warnings/Precautions:
May increase risk of infections. Chronic or history of recurrent infection. If a serious infection develops, monitor closely and discontinue until resolves. History of latent or active TB; consider anti-TB therapy prior to initiation. Evaluate for TB infection prior to initiating. Monitor for active TB during and after therapy. Patients with active TB infection: do not initiate. Inflammatory bowel disease; monitor. Discontinue if anaphylaxis or serious allergic reactions occur. Complete immunizations based on current guidelines prior to initiation. Latex allergy (Sensoready pen and prefilled syringe only). Pregnancy. Nursing mothers.
COSENTYX Classification:
Interleukin-17A antagonist.
COSENTYX Interactions:
Concomitant live vaccines: not recommended. Non-live vaccines: may get suboptimal response. Concomitant CYP450 substrates with a narrow therapeutic index (eg, warfarin, cyclosporine); monitor and consider adjusting dose.
Adverse Reactions:
Nasopharyngitis, diarrhea, upper respiratory tract infection; inflammatory bowel disease, hypersensitivity reactions, other serious infections.
Generic Drug Availability:
NO
How Supplied:
Single-use Sensoready pen—1, 2; Single-use prefilled syringe—1, 2; Single-use vial—1
Pricing for COSENTYX
Psoriasis:
Indications for COSENTYX:
Moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
Adult Dosage:
Rotate inj site (eg, upper arms, thighs, or any quadrant of abdomen). ≥18yrs: 300mg (given as two 150mg SC injections) at Weeks 0, 1, 2, 3, and 4 then 300mg every 4 weeks. For some patients, 150mg dose may be acceptable.
Children Dosage:
<18yrs: not evaluated.
COSENTYX Warnings/Precautions:
May increase risk of infections. Chronic or history of recurrent infection. If a serious infection develops, monitor closely and discontinue until resolves. History of latent or active TB; consider anti-TB therapy prior to initiation. Evaluate for TB infection prior to initiating. Monitor for active TB during and after therapy. Patients with active TB infection: do not initiate. Inflammatory bowel disease; monitor. Discontinue if anaphylaxis or serious allergic reactions occur. Complete immunizations based on current guidelines prior to initiation. Latex allergy (Sensoready pen and prefilled syringe only). Pregnancy. Nursing mothers.
COSENTYX Classification:
Interleukin-17A antagonist.
COSENTYX Interactions:
Concomitant live vaccines: not recommended. Non-live vaccines: may get suboptimal response. Concomitant CYP450 substrates with a narrow therapeutic index (eg, warfarin, cyclosporine); monitor and consider adjusting dose.
Adverse Reactions:
Nasopharyngitis, diarrhea, upper respiratory tract infection; inflammatory bowel disease, hypersensitivity reactions, other serious infections.
Generic Drug Availability:
NO
How Supplied:
Single-use Sensoready pen—1, 2; Single-use prefilled syringe—1, 2; Single-use vial—1
